Search Results - "Perez, Lia E"

Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow by BOUCHER, Kelly, PARQUET, Nancy, WIDEN, Raymond, SHAIN, Kenneth, BAZ, Rachid, ALSINA, Melissa, KOOMEN, John, ANASETTI, Claudio, DALTON, William, PEREZ, Lia E

“…In myeloma, B cells and plasma cells show a clonal relationship. Clonotypic B cells may represent a tumor-initiating compartment or cancer stem cell…”
Get full text

Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion–Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid Leukemia by YANAMANDRA, Niranjan, COLACO, Nandita M, PARQUET, Nancy A, BUZZER, Robert W, BOULWARE, David, WRIGHT, Gabriela, PEREZ, Lia E, DALTON, William S, BEAUPRE, Darrin M

“…It has been established in preclinical models of multiple myeloma and acute myeloid leukemia (AML) that the bone marrow microenvironment provides protection…”
Get full text

SH2-inositol phosphatase 1 negatively influences early megakaryocyte progenitors by Perez, Lia E, Desponts, Caroline, Parquet, Nancy, Kerr, William G

“…The SH2-containing-5'inositol phosphatase-1 (SHIP) influences signals downstream of cytokine/chemokine receptors that play a role in megakaryocytopoiesis,…”
Get full text

Increased plasma levels of stromal-derived factor-1 (SDF-1/CXCL12) enhance human thrombopoiesis and mobilize human colony-forming cells (CFC) in NOD/SCID mice by Perez, Lia E, Alpdogan, Onder, Shieh, Jae-Hung, Wong, Donald, Merzouk, Ahmed, Salari, Hassan, O'Reilly, Richard J, van den Brink, Marcel R.M, Moore, Malcolm A.S

“…Stromal-derived factor-1 (SDF-1/CXCL12) is chemotactic for lympho/hematopoietic stem cells. We have previously shown that increasing peripheral blood (PB)…”
Get full text

Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft‐versus‐host disease score by Kharfan‐Dabaja, Mohamed A., Sheets, Kyle, Kumar, Ambuj, Murthy, Hemant S., Nishihori, Taiga, Tsalatsanis, Athanasios, Mina, Alain, Mathews, John, Ayala, Ernesto, Chavez, Julio, Perez, Lia E., Betts, Brian C., Anasetti, Claudio, Pidala, Joseph

“…Summary Hypoalbuminaemia has been previously described to predict worse non‐relapse mortality (NRM) and inferior overall survival (OS) in allogeneic…”
Get full text

ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation by Hansen, Doris K., Kim, Jongphil, Thompson, Zachary, Hussaini, Mohammad, Nishihori, Taiga, Ahmad, Anam, Elmariah, Hany, Faramand, Rawan, Mishra, Asmita, Davila, Marco L., Khimani, Farhad, Lazaryan, Aleksandr, Sallman, David, Liu, Hien, Perez, Lia E., Fernandez, Hugo, Nieder, Michael L., Lancet, Jeffrey E., Pidala, Joseph A., Anasetti, Claudio, Bejanyan, Nelli

“…European LeukemiaNet (ELN) 2017 risk stratification by genetics is prognostic of outcomes in patients with acute myeloid leukemia (AML). However, the…”
Get full text

Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma by Perez, Lia E., Parquet, Nancy, Meads, Mark, Anasetti, Claudio, Dalton, William

“…Objectives:  Hematopoietic stroma promotes resistance to immune control by APO2L/TRAIL in multiple myeloma (MM) cells in part by increasing synthesis of the…”
Get full text

NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020 by Becker, Pamela Sue, Griffiths, Elizabeth A, Alwan, Laura M, Bachiashvili, Kimo, Brown, Anna, Cool, Rita, Curtin, Peter, Dinner, Shira, Gojo, Ivana, Hicks, Ashley, Kallam, Avyakta, Kidwai, Wajih Zaheer, Kloth, Dwight D, Kraut, Eric H, Landsburg, Daniel, Lyman, Gary H, Miller, Ryan, Mukherjee, Sudipto, Patel, Shiven, Perez, Lia E, Poust, Adam, Rampal, Raajit, Rosovsky, Rachel, Roy, Vivek, Rugo, Hope S, Shayani, Sepideh, Vasu, Sumithira, Wadleigh, Martha, Westbrook, Kelly, Westervelt, Peter, Burns, Jennifer, Keller, Jennifer, Pluchino, Lenora A

“…Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic…”
Get more information

Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology by Crawford, Jeffrey, Becker, Pamela Sue, Armitage, James O, Blayney, Douglas W, Chavez, Julio, Curtin, Peter, Dinner, Shira, Fynan, Thomas, Gojo, Ivana, Griffiths, Elizabeth A, Hough, Shannon, Kloth, Dwight D, Kuter, David J, Lyman, Gary H, Mably, Mary, Mukherjee, Sudipto, Patel, Shiven, Perez, Lia E, Poust, Adam, Rampal, Raajit, Roy, Vivek, Rugo, Hope S, Saad, Ayman A, Schwartzberg, Lee S, Shayani, Sepideh, Talbott, Mahsa, Vadhan-Raj, Saroj, Vasu, Sumithira, Wadleigh, Martha, Westervelt, Peter, Burns, Jennifer L, Pluchino, Lenora

“…Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive chemotherapy to reduce the incidence of neutropenia. This…”
Get more information

Maximally Tolerated Busulfan Systemic Exposure in Combination with Fludarabine as Conditioning before Allogeneic Hematopoietic Cell Transplantation by Perkins, Janelle B, Kim, Jongphil, Anasetti, Claudio, Fernandez, Hugo F, Perez, Lia E, Ayala, Ernesto, Kharfan-Dabaja, Mohamed A, Tomblyn, Marcie R, Sullivan, Daniel M, Pidala, Joseph A, Field, Teresa L

“…Systemic exposure to high-dose busulfan has been correlated with efficacy and toxicity after hematopoietic cell transplantation for malignancy. We used the…”
Get full text

Xenotransplantation of immunodeficient mice with mobilized human blood CD34+ cells provides an in vivo model for human megakaryocytopoiesis and platelet production by Perez, Lia E., Rinder, Henry M., Wang, Chao, Tracey, Jayne B., Maun, Noel, Krause, Diane S.

“…The study of megakaryocytopoiesis has been based largely on in vitro assays. We characterize an in vivo model of megakaryocyte and platelet development in…”
Get full text

JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 cells: Final Phase II Trial Results by Pidala, Joseph A, Holtan, Shernan G, Walton, Kelly, Kim, Jongphil, Cao, Biwei, Elmariah, Hany, Mishra, Asmita, Bejanyan, Nelli, Nishihori, Taiga, Khimani, Farhad, Perez, Lia E, Faramand, Rawan G, Davila, Marco L, McSain, Shannon, Pleskow, Jordan, Baron, Jeffrey, Anasetti, Claudio, Moran Segura, Carlos M, Weisdorf, Daniel J, Blazar, Bruce R, Miller, Jeffrey S, Bachanova, Veronika, El Jurdi, Najla, Betts, Brian C

“…Our phase I graft-versus-host disease (GVHD) prevention trial of JAK2 inhibitor, pacritinib, (recommended phase II dose: 100mg po BID day 0 to +70) plus…”
Get full text

Phase II Study of CD4+ -Guided Pentostatin Lymphodepletion and Pharmacokinetically Targeted Busulfan as Conditioning for Hematopoietic Cell Allografting by Kharfan-Dabaja, Mohamed A, Anasetti, Claudio, Fernandez, Hugo F, Perkins, Janelle, Ochoa-Bayona, Jose L, Pidala, Joseph, Perez, Lia E, Ayala, Ernesto, Field, Teresa, Alsina, Melissa, Nishihori, Taiga, Locke, Frederick, Pinilla-Ibarz, Javier, Tomblyn, Marcie

“…Abstract One limitation of reduced-intensity preparative regimens is potential for graft failure. We have developed a regimen that targets CD4+ lymphodepletion…”
Get full text

a Combination of Ex Vivo and Computational Models Predicts Clinical Response in MM Treatment Combinations of Proteasome Inhibitors, Imids, Nuclear Export Inhibitors and Alkylating Agents by Silva, Ariosto, Silva, Maria, Jacobson, Timothy, Meads, Mark B, Distler, Allison, Collins, Aunshka, Cubitt, Chris, Perez, Lia E, Baz, Rachid, Rebatchouk, Dmitri, Gatenby, Robert, Shain, Kenneth H.

“…Introduction: Multiple myeloma is a heterogeneous plasma cell neoplasm that remains all but incurable despite significant advances in treatment. We anticipate…”
Get full text

A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT by DeFilipp, Zachariah, Kim, Haesook T, Cheng, Guang-Shing, Hamilton, Betty K, Chhabra, Saurabh, Hamadani, Mehdi, Sandhu, Karamjeet Singh, Perez, Lia E, Lee, Catherine, Brennan, Timothy L, Garrelts, Cassandra, Brown, Bergin M, Gallagher, Kathleen M E, Newcomb, Richard A, El-Jawahri, Areej, Chen, Yi-Bin

“…Bronchiolitis obliterans syndrome (BOS) occurring after allogeneic hematopoietic cell transplantation (HCT) is a high-risk manifestation of chronic…”
Get full text

NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022 by Griffiths, Elizabeth A, Roy, Vivek, Alwan, Laura, Bachiashvili, Kimo, Baird, John, Cool, Rita, Dinner, Shira, Geyer, Mark, Glaspy, John, Gojo, Ivana, Hicks, Ashley, Kallam, Avyakta, Kidwai, Wajih Zaheer, Kloth, Dwight D, Kraut, Eric H, Landsburg, Daniel, Lyman, Gary H, Mahajan, Anjlee, Miller, Ryan, Nachar, Victoria, Patel, Seema, Patel, Shiven, Perez, Lia E, Poust, Adam, Riaz, Fauzia, Rosovsky, Rachel, Rugo, Hope S, Simon, Shayna, Vasu, Sumithira, Wadleigh, Martha, Westbrook, Kelly, Westervelt, Peter, Berardi, Ryan A, Pluchino, Lenora

“…The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile…”
Get more information

SH.sub.2-Inositol Phosphatase 1 Negatively Influences Early Megakaryocyte Progenitors by Perez, Lia E, Desponts, Caroline, Parquet, Nancy, Kerr, William G

“…Background The SH2-containing-5'inositol phosphatase-1 (SHIP) influences signals downstream of cytokine/chemokine receptors that play a role in…”
Get full text

Abstract LB-157: Overcoming T-regulatory effects towards developing a more effective immunotherapy targeting multiple myeloma by Chang, Lung-Ji, Han, Shuhong, Okada, Starlyn, Patel, Ekta, Yang, Li-jun, Moreb, Jan S., Pircher, Hanspeter, Perez, Lia E., Alsina, Melissa

“…Recent progress in dendritic cell (DC) and T cell therapies has offered a new avenue in treating multiple myeloma (MM). We have reported that MM patients' DCs…”
Get full text

Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression by Kharfan-Dabaja, Mohamed A, Anasetti, Claudio, Luis, Nathalie, Brand, Linda, Perkins, Janelle, Fernandez, Hugo F., Ochoa-Bayona, Jose Leonel, Nishihori, Taiga, Perez, Lia E, Ayala, Ernesto, Pinilla-Ibarz, Javier, Sokol, Lubomir, Pidala, Joseph, Locke, Frederick L, Sotomayor, Eduardo M., Field, Teresa, Tomblyn, Marcie

“…Abstract 3022▪FN2▪This icon denotes a clinically relevant abstract Introduction of reduced toxicity regimens for hematopoietic cell allografting is expanding…”
Get full text

Environmental Mediated-Immune Resistance (EM-IR) to APO2L/TRAIL Mediated Apoptosis by Perez, Lia E., Parquet, Nancy, Molisano, Marina, Shain, Ken, Alsina, Melisa, Anasetti, Claudio, Dalton, William

“…Resistance to chemotherapy arises in a complex microenvironment and it is essential to study how it influences apoptosis in order to identify novel therapeutic…”
Get full text